

Scientific References for INR PLLC Press Release November 2013

For further information please go to painbreakthrough.com

1. Freeman, B.J., et al., *Randomized, Double-blind, Placebo-Controlled, Trial of Transforaminal Epidural Etanercept for the Treatment of Symptomatic Lumbar Disc Herniation*. Spine (Phila Pa 1976), 2013. **38**(23): p. 1986-94.
2. Ohtori, S., et al., *Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study*. Spine (Phila Pa 1976), 2012. **37**(6): p. 439-44.
3. Sainoh, T., et al., *Intradiscal Administration of Tumor Necrosis Factor-Alpha Inhibitor, Etanercept, Clinically Improves Intractable Discogenic Low Back Pain: A Prospective Randomized Study*, in *International Society for the Study of the Lumbar Spine 40th Annual Meeting*. 2013: Scottsdale, Arizona.
4. Cohen, S.P., et al., *Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica*. Anesthesiology, 2009. **110**(5): p. 1116-26.
5. Tobinick, E.L., *Targeted etanercept for discogenic neck pain: uncontrolled, open-label results in two adults*. Clin Ther, 2003. **25**(4): p. 1211-8.
6. Tobinick, E.L. and S. Britschgi-Davoodifar, *Perispinal TNF-alpha inhibition for discogenic pain*. Swiss Med Wkly, 2003. **133**(11-12): p. 170-7.
7. Tobinick, E. and S. Davoodifar, *Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients*. Curr Med Res Opin, 2004. **20**(7): p. 1075-85.
8. Tobinick, E., *Perispinal etanercept for neuroinflammatory disorders*. Drug Discov Today, 2009. **14**(3-4): p. 168-77.
9. Tobinick, E., *Perispinal etanercept: a new therapeutic paradigm in neurology*. Expert Rev Neurother, 2010. **10**(6): p. 985-1002.
10. Kato, K., et al., *Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve*. Neuroscience, 2009. **160**(2): p. 492-500.
11. Chio, C.C., et al., *Therapeutic evaluation of etanercept in a model of traumatic brain injury*. J Neurochem, 2010. **115**(4): p. 921-9.
12. Clark, I.A., L.M. Alleva, and B. Vissel, *The roles of TNF in brain dysfunction and disease*. Pharmacol Ther, 2010. **128**(3): p. 519-48.
13. Watanabe, K., et al., *Etanercept attenuates pain-related behavior following compression of the dorsal root ganglion in the rat*. Eur Spine J, 2011. **20**(11): p. 1877-84.
14. Shen, C.H., et al., *Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats*. Anesth Analg, 2011. **112**(2): p. 454-9.
15. Tobinick, E., et al., *Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury : An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept*. CNS Drugs, 2012. **26**(12): p. 1051-70.
16. Lei, B., et al., *Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage*. J Neuroinflammation, 2013. **10**(1): p. 103.

17. King, M.D., C.H. Alleyne, Jr., and K.M. Dhandapani, *TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice*. *Neurosci Lett*, 2013. **542**: p. 92-6.
18. Iwatsuki, K., et al., *Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain*. *PLoS One*, 2013. **8**(2): p. e57721.
19. Boivin, N., et al., *The combination of valacyclovir with an anti-TNF alpha antibody [etanercept] increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis*. *Antiviral Research*, 2013. **in press**, <http://dx.doi.org/10.1016/j.antiviral.2013.10.007>.
20. U.S. patent 6,419,944 to Edward Tobinick M.D.